MONA AL MUKADDAM MD
Prescription History 1043400567
Internal Medicine - Endocrinology, Diabetes & Metabolism in Philadelphia, PA


Quality Rating: 85.48 out of 100 score

NPI Status: Active since July 31, 2007

Contact Information

3400 CIVIC CENTER BLVD.
WEST PAVILION, 4TH FLOOR
PHILADELPHIA, PA
ZIP 19104
Phone: (215) 662-2300
Fax: (215) 614-0418

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MONA AL MUKADDAM MD, an active Endocrinology, Diabetes & Metabolism specialist practicing in Philadelphia, PA. Our medical registry currently tracks 16 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 986 documented patient claims. Among these therapy options, the most frequently utilized medication is Tymlos, which accounts for 305 claims alone.


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 152
30-Day Fills 371.2
Days Supply 11,073
PA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills90.4
Peer Average Days Supply2,652
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 245.5% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,258.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.44

State Avg Cost Per Claim

$11.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Calcitriol

Generic Formulation: CalcitriolSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 16
30-Day Fills 41.2
Days Supply 1,236
PA State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills84.0
Peer Average Days Supply2,448
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.8% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $299.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.74

State Avg Cost Per Claim

$24.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.

Therapeutic Applications

Calcitriol is a man-made active form of vitamin D. Most people get enough vitamin D from exposure to the sun and from fortified food products (such as dairy products, vitamins). Vitamin D helps control parathyroid hormone and the levels of certain minerals (such as calcium, phosphorus) that are needed for building and keeping strong bones. Before regular vitamin D can be used by the body, it needs to be changed to the active form by the liver and kidneys. Calcitriol is used in patients with kidney disease who can't make enough of the active form of Vitamin D. This medication is also used to prevent and treat certain types of calcium/phosphorus/parathyroid problems that can happen with long-term kidney dialysis or hypoparathyroidism. Calcitriol is usually used along with specific diet recommendations and sometimes other medications.

Cinacalcet Hcl

Generic Formulation: Cinacalcet HclSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 33
30-Day Fills 49.0
Days Supply 1,470
PA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills33.9
Peer Average Days Supply964
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 32.0% more claims than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,163.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$550.40

State Avg Cost Per Claim

$508.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Cinacalcet is used to treat increased amounts of a certain hormone (parathyroid) in people with long-term kidney disease who are on dialysis. It is also used to treat increased amounts of calcium in people with an overactive parathyroid gland or in people with cancer of the parathyroid gland. Cinacalcet works by decreasing the amount of parathyroid hormone, calcium, and phosphorus in your body. Having the right amount of these substances in your body helps to prevent bone disease.

Forteo

Generic Formulation: TeriparatideSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 106
30-Day Fills 107.8
Days Supply 3,038
PA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.4
Peer Average Days Supply636
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 404.8% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $487,898.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,602.82

State Avg Cost Per Claim

$4,369.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Therapeutic Applications

Teriparatide is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. It is similar to a natural hormone in your body (parathyroid hormone). It works by increasing bone mass and strength. This effect helps to decrease the risk of getting a fracture. This medication is not recommended for use in children or young adults whose bones are still growing.

Hydrochlorothiazide

Generic Formulation: HydrochlorothiazideSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 16
30-Day Fills 30.0
Days Supply 900
PA State Average Benchmarks
Peer Average Claims79.0
Peer Average 30-Day Fills192.2
Peer Average Days Supply5,720
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.7% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $111.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.00

State Avg Cost Per Claim

$5.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.

Therapeutic Applications

This medication is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Hydrochlorothiazide belongs to a class of drugs known as diuretics/water pills. It works by causing you to make more urine. This helps your body get rid of extra salt and water. This medication also reduces extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, or kidney disease. This can lessen symptoms such as shortness of breath or swelling in your ankles or feet.

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 51
30-Day Fills 140.1
Days Supply 4,203
PA State Average Benchmarks
Peer Average Claims171.0
Peer Average 30-Day Fills360.6
Peer Average Days Supply10,486
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.2% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $906.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.77

State Avg Cost Per Claim

$16.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Metformin Hcl Er

Generic Formulation: Metformin HclSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 12
30-Day Fills 32.0
Days Supply 960
PA State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills124.6
Peer Average Days Supply3,702
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.9% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $289.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.09

State Avg Cost Per Claim

$13.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)

Therapeutic Applications

Metformin is used with a proper diet and exercise program and possibly with other medications to control high blood sugar. It is used in patients with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Metformin works by helping to restore your body's proper response to the insulin you naturally produce. It also decreases the amount of sugar that your liver makes and that your stomach/intestines absorb.

Mounjaro

Generic Formulation: TirzepatideSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 11
30-Day Fills 20.0
Days Supply 591
PA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills20.1
Peer Average Days Supply573
Conservative Utilization

This provider writes prescriptions for this formulation 35.3% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,656.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,059.68

State Avg Cost Per Claim

$1,200.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A glucose-dependent insulinotropic polypeptide (GIP) receptor and Glucose-like peptide-1 (GLP-1) receptor agonist to enhance glycemic control in adults with TYPE 2 DIABETES MELLITUS.

Therapeutic Applications

Tirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. It lowers blood sugar by causing the release of your body's natural insulin and decreasing the amount of sugar your liver makes.

Nano 2nd Gen Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 14
30-Day Fills 40.7
Days Supply 1,220
PA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills64.9
Peer Average Days Supply1,918
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.7% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,105.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$78.96

State Avg Cost Per Claim

$93.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Prolia

Generic Formulation: DenosumabSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 17
30-Day Fills 102.0
Days Supply 3,060
PA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills145.0
Peer Average Days Supply4,346
Conservative Utilization

This provider writes prescriptions for this formulation 32.0% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $26,806.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,576.87

State Avg Cost Per Claim

$1,491.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone remodeling. It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS.

Therapeutic Applications

Denosumab is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause (in women), as you age, if someone in your family has osteoporosis, or if you take certain medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Denosumab belongs to a class of drugs called monoclonal antibodies. It prevents certain cells in the body (osteoclasts) from breaking down bone.

Risedronate Sodium

Generic Formulation: Risedronate SodiumSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 43
30-Day Fills 68.4
Days Supply 1,994
PA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills40.8
Peer Average Days Supply1,199
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 104.8% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,334.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$100.80

State Avg Cost Per Claim

$133.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Therapeutic Applications

Risedronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Risedronate belongs to a class of medications called bisphosphonates.

Synthroid

Generic Formulation: Levothyroxine SodiumSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 34
30-Day Fills 77.7
Days Supply 2,330
PA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills110.1
Peer Average Days Supply3,293
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,524.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$103.67

State Avg Cost Per Claim

$70.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Teriparatide

Generic Formulation: TeriparatideSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 52
30-Day Fills 52.0
Days Supply 1,456
PA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.1
Peer Average Days Supply568
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 160.0% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $133,901.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,575.04

State Avg Cost Per Claim

$2,479.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Therapeutic Applications

Teriparatide is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. It is similar to a natural hormone in your body (parathyroid hormone). It works by increasing bone mass and strength. This effect helps to decrease the risk of getting a fracture. This medication is not recommended for use in children or young adults whose bones are still growing.

Tymlos

Generic Formulation: AbaloparatideSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 305
30-Day Fills 313.0
Days Supply 9,340
PA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills33.4
Peer Average Days Supply999
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 883.9% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $826,793.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,710.80

State Avg Cost Per Claim

$2,501.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Abaloparatide is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. It is similar to a natural hormone in your body (parathyroid hormone). It works by increasing bone mass and strength. This effect helps to decrease the risk of getting a fracture. This medication should not be used for children or young adults whose bones are still growing.

Ultra-Fine Mini Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 113
30-Day Fills 344.2
Days Supply 10,330
PA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills41.8
Peer Average Days Supply1,228
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 438.1% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,714.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$59.42

State Avg Cost Per Claim

$81.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Ultra-Fine Nano Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 11
30-Day Fills 34.7
Days Supply 1,040
PA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills44.9
Peer Average Days Supply1,307
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.2% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $682.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$62.02

State Avg Cost Per Claim

$80.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MONA AL MUKADDAM MD provides transparency into local medical care patterns within Philadelphia, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Endocrinology, Diabetes & Metabolism** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.